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Abstract 25 
Widespread expression of leptin and its receptor in developing cartilage and bone suggests 26 
that leptin may regulate bone growth and development in the fetus.  Using micro-computed 27 
tomography, this study investigated the effects of exogenous leptin and leptin receptor 28 
antagonism on aspects of bone structure in the sheep fetus during late gestation.  From 125-29 
130 days of gestation (term ~145 days), chronically-catheterised singleton sheep fetuses were 30 
infused intravenously for five days with either saline (0.9% saline, n=13), recombinant ovine 31 
leptin at two doses (0.6 mg/kg/day LEP1, n=10 or 1.4 mg/kg/day LEP2, n=7) or recombinant 32 
super-active ovine leptin receptor antagonist (4.6 mg/kg/day SOLA, n=6).  No significant 33 
differences in plasma insulin-like growth factor-I, osteocalcin, calcium, inorganic phosphate 34 
or alkaline phosphatase were observed between treatment groups.  Total femur midshaft 35 
diameter and metatarsal lumen diameter were narrower in male fetuses treated with 36 
exogenous leptin.  In a fixed length of femur midshaft, total and bone volumes were reduced 37 
by the higher dose of leptin; non-bone space volume was lower in both groups of leptin-38 
treated fetuses.  Leptin infusion caused increments in femur porosity and connectivity density, 39 
and vertebral trabecular thickness.  Leptin receptor antagonism decreased trabecular spacing 40 
and increased trabecular number, degree of anisotrophy and connectivity density in the 41 
lumbar vertebrae.  The increase in vertebral porosity observed following leptin receptor 42 
antagonism was greater in the male, compared to female, fetuses.  Therefore, leptin may have 43 
a role in the growth and development of the fetal skeleton, dependent on the concentration of 44 
leptin, sex of the fetus and bone type examined. 45 
46 
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Introduction 47 
Leptin is a hormone primarily secreted by white adipose tissue which was first identified as 48 
an important regulator of appetite and energy expenditure (50), and, in adult life, is now 49 
known to have a wide range of biological actions, including modulation of immune, 50 
neuroendocrine and reproductive function and bone metabolism (37, 47).  Before birth, the 51 
expression of leptin and its receptors is widespread in fetal and placental tissues, although, to 52 
date, the role of leptin in the control of growth and development in utero is poorly understood 53 
(14).  In the mouse fetus, mRNA and protein for leptin and its long-form signalling receptor, 54 
Ob-Rb, have been localised in particular to the skeleton, including vertebrae, ribs and the 55 
bones of the fore- and hind-limbs (7, 23, 24).  Leptin and its receptor were expressed in 56 
different cell types in the rib of the murine fetus, indicating that leptin may exert paracrine as 57 
well as endocrine actions in the developing cartilage-bone (23). 58 
 59 
In human fetuses sampled by cordocentesis at 18-35 weeks of gestation, a negative correlation 60 
has been observed between plasma leptin and a marker of bone resorption (cross-linked 61 
carboxy-terminal telopeptode of type I collagen; 36).  Leptin may, therefore, inhibit bone 62 
resorption to promote growth of the fetal skeleton.  Indeed, at birth, umbilical leptin 63 
concentration has been shown to correlate positively with whole body bone mineral content 64 
and estimated bone density in human neonates (27).  However, in a study examining 65 
umbilical samples from large, small and average-sized babies, plasma leptin did not relate to 66 
whole body bone mineral density or content determined within the first 24 hours of life (1).  67 
In addition, there are conflicting reports detailing changes in bone density in infants born to 68 
diabetic mothers who are exposed to high concentrations of leptin in utero (18, 29, 42). 69 
 70 
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A variety of experimental studies in vivo and in vitro have demonstrated that the actions of 71 
leptin on bone growth and development in postnatal animals are complex and depend on 72 
factors including i) the leptin dose, ii) route of administration, iii) age of the animal and iv) 73 
the skeletal region and type of bone tissue examined (30).  In prepubertal mice, the epiphyseal 74 
growth plate has been shown to express Ob-Rb and leptin treatment increases the size of the 75 
tibial growth plate in association with proliferation and differentiation of chondrocytes (16).  76 
Leptin receptors are also present in isolated fetal rat osteoblasts and in primary cultures of 77 
adult osteoblasts and chondrocytes (9, 43).  Studies in vitro have shown that leptin directly 78 
stimulates proliferation and differentiation of osteoblasts, while inhibiting differentiation of 79 
bone adipocytes (9, 45).  In contrast, it has also been reported in rodents and sheep that leptin 80 
can suppress bone formation indirectly by hypothalamic control of sympathetic and cocaine 81 
amphetamine regulated transcript (CART) pathways (12, 13, 40, 49).  Both hypothalamic and 82 
peripheral administration of leptin have been shown to correct the skeletal abnormalities seen 83 
in leptin-deficient ob/ob mice, in association with elevated serum insulin-like growth factor-I 84 
(IGF-I) and osteocalcin levels, a marker of osteoblast activity (2, 26, 46).  The overall effect 85 
of leptin on bone development, therefore, may depend upon the balance between peripheral 86 
and central leptin signalling pathways, although the relative importance of these mechanisms 87 
in bone remodelling remains controversial (30). 88 
 89 
The role of leptin in the control of bone growth and development before birth is unclear.  90 
Previous studies have shown that plasma leptin concentration is elevated in hypothyroid fetal 91 
sheep that show abnormalities in bone growth and development (22, 28), although the extent 92 
to which leptin contributes to the bone phenotype in this model remains unknown.  The 93 
present study investigated the effects of leptin treatment and leptin receptor antagonism on 94 
plasma IGF-I and osteocalcin concentrations, and aspects of bone structure determined by 95 
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micro-computed tomography, in the sheep fetus during late gestation.  The study hypothesised 96 
that exogenous leptin treatment would promote, while antagonism of the leptin receptor 97 
would inhibit, the normal development of bone, and plasma IGF-I and osteocalcin 98 
concentrations, in the sheep fetus. 99 
 100 
Methods 101 
Animals 102 
All surgical and experimental procedures were approved by the local animal ethics committee 103 
and were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 104 
under Home Office project licence PPL70/7645.  Thirty-six Welsh Mountain sheep with 105 
singleton pregnancies of known gestational age were used in this study.  The pregnant ewes 106 
were housed in individual pens and maintained on 200g/kg concentrates with free access to 107 
hay, water and a salt-lick block.  108 
 109 
Surgical procedures 110 
The pregnant ewes were fasted for 18-24 h before surgery with free access to water.  At 111 
between 118 and 120 days of pregnancy (term 145 ± 2 days) and under general anaesthesia 112 
(1.5% halothane in O2-N2O), catheters were inserted into the femoral artery and vein of the 113 
fetus and the femoral artery of the ewe using techniques previously described (8).  All 114 
catheters were exteriorised through the flank of the ewe and secured in a bag sutured to the 115 
skin.  The vascular catheters were flushed daily with heparinised saline solution (100 IU 116 
heparin in 0.9% saline) from the day after surgery.  At surgery, all fetuses were administered 117 
i.v. with 100 mg ampicillin (Penbritin, Beecham Animal Health, Brentford, UK) and 2 mg 118 
gentamycin (Frangen-100, Biovet, Mullingar, Ireland).  Ewes were administered with 119 
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antibiotics i.m. (Depocillin, Mycofarm, Cambridge, UK) on the day of surgery and for 3 days 120 
thereafter.  121 
 122 
Experimental procedures 123 
Starting at 125 days of gestation and for a period of 5 days, one group of fetuses was infused 124 
i.v. with saline (0.9% sodium chloride, n=13) while a further three groups received either 125 
recombinant ovine leptin at two doses (0.56 ± 0.02 mg/kg/day LEP1, n =10 or 1.35 ± 0.11 126 
mg/kg/day LEP2, n=7) or recombinant super-active ovine leptin antagonist (4.56 ± 0.24 127 
mg/kg/day SOLA, n=6; Protein Laboratories Rehovot, Israel; 17, 34).  The doses of leptin 128 
administered increased circulating leptin to supra-physiological concentrations in the sheep 129 
fetus (10) and by a similar magnitude as that seen in the umbilical blood of babies born to 130 
women with obesity and/or diabetes during pregnancy (6, 18).  The leptin antagonist was 131 
produced by D23L/L39A/D40A/F41A mutation of recombinant ovine leptin (34).  The leptin 132 
mutant competes with endogenous leptin for binding sites on all forms of the leptin receptor 133 
but lacks biological activity (34).  In fetal sheep, a less potent form of the recombinant ovine 134 
leptin receptor antagonist (mutant L39A/D40A/FA1A/I42A, OLA) at a dose of 1.5 mg/kg/day 135 
i.v. has previously been shown to reduce STAT-3 phosphorylation by approximately 50% in 136 
the adrenal cortex (11).  The treatments were administered via the fetal venous catheter at a 137 
rate of 3 ml/day using a Graseby portable infusion pump.  Arterial blood from the fetus and 138 
ewe (3 ml) was collected daily from 2 days before and during the 5-day infusion period.   139 
 140 
On the fifth day of infusion at 130 days of gestation, the fetuses were delivered by Caesarean 141 
section under maternal general anaesthesia (20 mg/kg sodium pentobarbitone i.v.).  After 142 
administration of a lethal dose of barbiturate (200 mg/kg sodium pentobarbitone i.v.) to the 143 
ewe and fetus, the fetus was weighed and a variety of tissues were collected.  In all fetuses, 144 
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bodyweight, crown-rump length and fore-limb (humerus, radius and metacarpus) and hind-145 
limb (femur, tibia and metatarsal) lengths were measured.  Three selected bones from the 146 
axial and appendicular skeleton (femur, metatarsal and lumbar vertebra L2-L4) were dissected 147 
and frozen at -80°C.  148 
 149 
Biochemical analyses 150 
All blood samples were collected into EDTA-containing tubes and centrifuged at 1000g for 5 151 
minutes at 4°C; the plasma was stored at -20°C until analysis.  Plasma concentrations of 152 
leptin and IGF-I were determined by RIA as previously described (4, 15).  The intra-assay 153 
coefficients of variation were 4-5%, and the minimum levels of detection were 0.09 and 0.08 154 
ng/ml, respectively.  Plasma osteocalcin concentrations were determined using an ELISA kit 155 
(Immunodiagnostics Systems Ltd, Boldon, UK); the intra-assay coefficient of variation was 156 
4% and the lower limit of assay detection was 0.5 ng/ml.  Total plasma calcium, inorganic 157 
phosphate and alkaline phosphatase concentrations were measured using a Siemens 158 
Dimension RXL-2 autoanalyser (Siemens Healthcare, Camberley, UK).  The minimum levels 159 
of detection were 1.25 mM, 0.1 mM and 11 U/l, respectively. 160 
 161 
Micro-computed tomography 162 
The femur, metatarsal and lumbar vertebrae were scanned using a Skyscan 1176 in vivo 163 
micro-CT scanner (Bruker micro-CT, Kontich, Belgium).  All scans were taken at 50 kV, 50 164 
μA with 0.5 mm aluminium filter and 0.4° rotation step.  Individual 2D cross-sectional images 165 
were reconstructed using Bruker NRecon software version 1.6.5.8.  Voxel resolution was 18 166 
µm.  Reconstructed images were analysed using Bruker CTAn software version 1.13.5.1 to 167 
calculate bone volume, bone volume to total volume ratio, bone surface to bone volume ratio, 168 
and trabecular thickness, number and spacing.  In addition, measurements were made of 169 
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trabecular pattern factor (relative convex or concave nature of the total bone surface), 170 
porosity, connectivity density, structural model index (SMI, surface convexity) and degree of 171 
anisotropy (DOA, orientation of trabeculae).  In the femur and metatarsal, a 3.56 mm length 172 
of midshaft bone was assessed for volumes of lumen, bone tissue and space between the bone 173 
tissue. 174 
 175 
Statistical analysis 176 
All data were tested for normality, and parametric and non-parametric tests were used as 177 
appropriate (SPSS Statistics 20 statistical analysis software, Richmond, USA).  Values 178 
obtained from the four groups were compared separately to assess the effects of leptin 179 
infusion (saline, LEP1, LEP2) and the effects of leptin receptor antagonism (saline, SOLA).  180 
Initially, all data were analysed by two-way ANOVA, with treatment and sex of the fetus as 181 
factors, followed by Tukey’s post hoc test.  Where data were not influenced by the sex of the 182 
fetus, one-way ANOVA followed by Tukey’s post hoc test, or paired or Student’s unpaired t-183 
test as appropriate, was used to assess the effects of treatment.  Differences where p<0.05 184 
were regarded as significant.  All data are presented as mean ± SEM values.  185 
 186 
Results 187 
Plasma hormone and metabolite concentrations 188 
Plasma leptin concentrations in the fetuses treated with recombinant ovine leptin increased 189 
significantly over the period of the infusion (p<0.05, Table 1).  The RIA method used to 190 
measure plasma leptin detected the recombinant ovine leptin receptor antagonist as leptin and, 191 
therefore, the apparent plasma leptin concentrations in the fetuses infused with the antagonist 192 
were also increased from pre-treatment levels (p<0.05, Table 1).  On the fifth day of 193 
treatment, plasma leptin concentrations in the fetuses infused with either leptin or leptin 194 
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receptor antagonist were significantly higher than those observed in the control fetuses 195 
infused with saline; values were increased by leptin infusion in a dose-dependent manner 196 
(p<0.05, Table 1). 197 
 198 
Plasma concentrations of IGF-I, osteocalcin, calcium and inorganic phosphate did not differ 199 
between the treatment groups before or after infusion, and were unaffected by administration 200 
of leptin or leptin receptor antagonist over five days (Table 1).  Plasma alkaline phosphatase 201 
concentrations were increased by gestational age over the five days of treatment in all the 202 
groups of fetuses (p<0.05, Table 1).  There was no difference in the change in plasma alkaline 203 
phosphatase observed over the period of study between the treatment groups (Table 1). 204 
 205 
Body morphometry 206 
No significant differences in fetal bodyweight, crown-rump length or limb lengths were 207 
observed between the treatment groups at the end of the 5-day infusion period, when 208 
measurements were made before dissection (Table 2).  When data from the fetuses treated 209 
with saline or the leptin receptor antagonist were assessed, a significant effect of sex was 210 
identified for the metatarsal, radius and metacarpal bone lengths (p<0.05 in all cases); 211 
however, although the data indicated that values were greater in the male compared to female 212 
fetuses, the results of the Tukey post-hoc tests failed to reach significance for each pair-wise 213 
comparison (p>0.05).  There were no interactions between sex and treatment for any of the 214 
measurements of body weight or limb length. 215 
 216 
Bone structure 217 
Exogenous leptin infusion 218 
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Femur midshaft diameter was significantly narrower in the fetuses of the LEP2 group 219 
compared to those infused with saline (p<0.05, Table 3); midshaft diameter in the LEP1 220 
fetuses was intermediate to the values observed in the saline and LEP2 fetuses (Table 3).    221 
When analysed by sex, femur midshaft diameter was significantly greater in the male 222 
compared to female fetuses of the saline group alone; midshaft diameter was reduced by 223 
leptin infusion in the male, but not female, fetuses of the LEP1 and LEP2 groups (p<0.05, 224 
Table 3). 225 
 226 
In a fixed length of femur midshaft bone, total volume was significantly lower in the LEP2-227 
treated fetuses, compared with the saline control group, while the values in the LEP1-treated 228 
fetuses were intermediate (p<0.05, Figure 1).  The midshaft volume composed of non-bone 229 
space was significantly decreased by leptin treatment in both LEP1 and LEP2 groups (p<0.05, 230 
Figure 1A).  In LEP1-treated fetuses, the non-bone space expressed as a proportion of the 231 
total volume was significantly lower than that observed in the saline-treated fetuses (p<0.05, 232 
Figure 1B).  A significant reduction in bone tissue volume was seen in the fetuses treated with 233 
the higher dose of leptin compared to those treated with the lower dose (p<0.05, Figure 1A).  234 
The bone surface to volume ratio in the femur tended to increase with leptin treatment, but 235 
this change failed to reach statistical significance (p=0.08, Table 3). 236 
 237 
In the saline control group alone, the midshaft lumen diameter of the metatarsal bone was 238 
significantly greater in the male than the female fetuses; midshaft lumen diameter was 239 
decreased by leptin infusion in male, but not female, fetuses of the LEP1 and LEP2 groups 240 
(p<0.05, Table 3).  In the fixed length of midshaft bone, the bone tissue volume was 241 
significantly lower in the fetuses treated with the higher dose of leptin compared to those 242 
treated with the lower dose (p<0.05, Figure 2A). 243 
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 244 
Significant increments in femur trabecular porosity and connectivity density, and vertebral 245 
trabecular thickness, were observed in the LEP1-infused fetuses compared to the control 246 
saline group (p<0.05, Figure 3); these parameters were also elevated  in the LEP2 fetuses but 247 
failed to differ significantly from the values in the saline control group (Figure 3).   248 
 249 
For all other parameters measured in the femur, metatarsal and lumbar vertebrae, no 250 
significant differences were observed between the fetuses infused with saline or leptin (Table 251 
3).  Leptin treatment influenced trabecular thickness (p=0.07) and DOA (p=0.08) in the 252 
metatarsal, and body length (p=0.09), bone surface to volume ratio (p=0.08), trabecular 253 
pattern factor (p=0.07) and structural model index (p=0.08) in the lumbar vertebrae, but these 254 
effects failed to reach statistical significance (Table 3).  255 
 256 
Leptin receptor antagonism 257 
In the lumbar vertebra, leptin receptor antagonism caused a significant decrease in trabecular 258 
spacing and increases in trabecular number, DOA and connectivity density (p<0.05, Figure 4).  259 
Lumbar vertebral porosity was also increased following treatment with the leptin receptor 260 
antagonist in a sex-dependent manner, with the increment in porosity greater in the male, 261 
compared to the female, fetuses (p<0.05, Figure 5). 262 
 263 
In the other bones, there were no significant differences in any of the other measured 264 
parameters between the fetuses infused with saline or the leptin antagonist (Table 4).  265 
Measurements of femur midshaft total diameter, metatarsal midshaft total and lumen 266 
diameter, and vertebral bone surface to volume ratio and structural model index were greater 267 
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in the male compared to female fetuses (p<0.05), but these were not affected by leptin 268 
receptor antagonism (Table 4). 269 
 270 
Discussion 271 
The findings of the present study demonstrate that exogenous leptin treatment and leptin 272 
receptor antagonism have differential effects on bone structure in the sheep fetus during late 273 
gestation, dependent on the bone type examined and, in some aspects, the sex of the fetus.  In 274 
the femur, exogenous leptin treatment caused significant decrements in total, bone and non-275 
bone space volumes and increments in trabecular porosity and connectivity density.  In 276 
addition, compared to the saline control group, a reduction in femur midshaft diameter was 277 
observed in the male, but not female, fetuses treated with exogenous leptin.  These findings 278 
show that supra-physiological concentrations of leptin impair femoral bone growth, although 279 
the trabecular bone may become a more organised and potentially stronger structure.  In 280 
contrast, leptin receptor antagonism predominantly affected the developing lumbar vertebra.  281 
Leptin receptor antagonism resulted in an increase in trabecular number, DOA and 282 
connectivity density, with less space between the structures and no change to trabecular 283 
thickness.  Therefore, while exogenous leptin promoted growth of vertebral trabeculae, the 284 
leptin receptor antagonist caused generation and organisation of the vertebral trabecular bone 285 
structure.  These findings indicate that leptin normally suppresses these aspects of bone 286 
development in the axial skeleton.  The responses to exogenous leptin and leptin receptor 287 
antagonism occurred without any change in circulating IGF-I, osteocalcin or other markers of 288 
bone turnover.  In newborn mice, primary ossification centres in the limb bones were enlarged 289 
in size following maternal treatment with leptin during mid-gestation (3).  The present study 290 
is the first to investigate the consequences of direct leptin administration to the fetus for its 291 
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bone structure, with potentially fewer confounding effects of leptin on maternal and placental 292 
physiology.   293 
 294 
Regional differences have been observed in the effects of leptin excess and deficiency on the 295 
appendicular and axial bones of the postnatal skeleton (19, 21).  Intracerebroventricular 296 
infusion of leptin in rats caused reductions in bone mineral content and density in the femur, 297 
but not the lumbar vertebra (19).  In ob/ob mice, the femur was reduced in length with lower 298 
mineralization and trabecular bone volume, while trabecular volume and bone mineral content 299 
and density were increased in the lumbar vertebrae (21).  The bone phenotype of the leptin-300 
deficient rodent, however, is complex as previous studies have shown greater bone mass in 301 
both the femur and vertebrae of ob/ob and leptin receptor-deficient db/db mice (12).  302 
Measurements of bone volume and trabecular number, thickness and mineral density were 303 
also elevated in the femur of the leptin-deficient rat, suggesting that leptin suppresses bone 304 
formation in this species (48).  The overall effects of leptin manipulation on bone structure 305 
may depend on the balance between the peripheral stimulatory and central inhibitory control 306 
of bone turnover by leptin, although the relative importance of these mechanisms, especially 307 
within specific regions of the skeleton, remains poorly understood (30).   308 
 309 
In the current study, the effects of exogenous leptin and leptin receptor antagonism on bone 310 
structure in the ovine fetus may be mediated by direct and/or indirect mechanisms, in 311 
particular via the hypothalamic relay.  Leptin receptors are expressed on developing bone 312 
cells in fetal rodents (7, 9, 23) and leptin stimulates proliferation of osteoblasts isolated from 313 
fetal rats in late gestation (9).  The hypothalamic control of bone development by sympathetic 314 
and CART neurones, and the role of leptin in modulating these pathways, are unknown in 315 
fetal life.  In the sheep fetus during late gestation, Ob-Rb mRNA has been localised to several 316 
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hypothalamic nuclei, including the arcuate nucleus and dorsomedial, ventromedial and 317 
paraventricular regions (31) and previous studies have shown that intracerebroventricular 318 
infusion of leptin has effects on swallowing movements and hypothalamic-pituitary-adrenal 319 
activity (25, 41).  The permeability of the blood-brain barrier to supra-physiological systemic 320 
concentrations of leptin and the leptin antagonist, however, remains to be established.  The 321 
leptin mutant antagonist can bind to all forms of the leptin receptor, including the soluble Ob-322 
Re which enables leptin to transfer across the blood-brain barrier.  The blood-brain barrier is 323 
functional in the ovine fetus from at least two-thirds of gestation although, in many regions of 324 
the brain, it is more permeable to small hydrophilic molecules in fetal compared to neonatal 325 
and adult life (44).  It is possible that the effects of the leptin receptor antagonist on vertebral 326 
bone structure in utero are largely due to prevention of the normal inhibitory effects of leptin 327 
on bone growth via the hypothalamic relay. 328 
 329 
Most studies using human and murine leptin receptors to examine receptor kinetics have 330 
shown that the equilibrium dissociation constant (KD) is in the sub-nanomolar range; KD 331 
values are reported to range from 0.1-15nM for leptin receptors in solution and 0.2-2.6nM for 332 
those attached to the cell surface, with variation between studies possibly dependent on the 333 
techniques and cell types used (38).  The mean plasma concentration of leptin in the saline-334 
infused control fetuses at 130 days of gestation was 0.04 nM in the present study, and rises to 335 
0.06 nM in sheep fetuses near term (35).  In the fetuses infused with recombinant leptin, the 336 
mean plasma leptin concentrations were 0.29 and 0.51 nM on the fifth day of infusion of the 337 
two leptin doses, LEP1 and LEP2, respectively.  Therefore, although plasma leptin 338 
concentrations achieved in the infused fetuses were significantly above the normal 339 
endogenous levels, they were still within the range of the leptin receptor KD. 340 
 341 
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It is also possible that exposure to supra-physiological concentrations of leptin may modify 342 
tissue expression of the leptin receptor and the activity of downstream signalling pathways.  343 
In a previous study examining the effect of leptin treatment on lung structure and function in 344 
fetal sheep, the five-day infusion of the lower LEP1 dose caused a significant increase in 345 
pulmonary leptin receptor mRNA abundance (10).  The expression and activity of leptin 346 
receptors in the bone and hypothalamus were not investigated in the present study, although it 347 
has been shown that long-term exposure to leptin in obese adult animals and human subjects 348 
leads to leptin insensitivity in the appetite networks of the hypothalamus (32).  349 
 350 
In the present study, sexual dimorphism was evident in a variety of bone measurements, and 351 
male fetuses appeared to be more sensitive to the actions of exogenous leptin and leptin 352 
receptor antagonism than female fetuses.  The mechanisms responsible, and the consequences 353 
for bone structure and mechanical strength in later life, remain to be determined.  Different 354 
patterns in circulating testosterone concentration have been reported in male and female sheep 355 
fetuses from mid-gestation (39) and there may be sex-specific expression of endocrine and 356 
other signalling pathways in developing bone.  Treatment of pregnant rats with leptin in mid-357 
gestation led to a lower birthweight, and greater longer term reductions in skeletal growth and 358 
bone mineral content, in male compared with female offspring (33).  It is possible that a 359 
longer duration of exposure to exogenous leptin and leptin receptor antagonism, and/or at 360 
different time points in bone development, would have led to more profound effects on the 361 
developing ovine skeleton in both sexes.   362 
 363 
In postnatal life, leptin is known to have an important role in the physiological adaptations to 364 
fasting: low circulating levels of leptin, due to reductions in body fat mass, lead to enhanced 365 
appetite and impaired fertility and body, including bone, growth (20).  In mice, leptin 366 
treatment has been shown to correct the reduction in tibial bone length induced by calorie 367 
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restriction, independent of IGF-I levels (16).  In addition, the effects of calorie restriction on 368 
bone formation are bone site-specific, with bone mineral content decreased in the femur and 369 
increased in the vertebra of mice undernourished over a six-month period (5).  Before birth, 370 
the role of leptin in the response to changes in nutrient availability is less clear.  In the sheep 371 
fetus, maternal undernutrition appears to have little effect on leptin production, although 372 
adipose leptin mRNA abundance and plasma leptin concentration are sensitive to levels of 373 
glucose, insulin, oxygen and glucocorticoids in utero (14).   374 
 375 
Perspectives and Significance 376 
This study has shown a role for leptin in the growth and development of the ovine fetal 377 
skeleton which is dependent on the leptin concentration, bone site and sex of the fetus.  378 
Further longer term studies are required to determine the extent to which physiological 379 
changes in leptin contribute to the endocrine control of bone growth during normal and 380 
suboptimal nutrition in utero.  In addition, it will be important to assess whether the changes 381 
observed in bone structure induced by variations in leptin activity before birth have 382 
consequences for bone function across the life-course.    383 
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Figure legends 580 
1.  Mean (± SEM) bone volumes (A) and percentage bone volumes (B) in a fixed length of 581 
midshaft femur from fetuses infused for five days with either saline, leptin (LEP1 and LEP2) 582 
or leptin antagonist (SOLA).  For comparisons between saline and leptin treatment groups, 583 
columns with different letters are significantly different from each other; uppercase letters 584 
indicate differences in the total volume, and lowercase letters at the SEM bars indicate 585 
differences in volume compartments (one-way ANOVA, p<0.05).  Compartments with no 586 
letters at the SEM bars are not significantly different from each other (p>0.05). 587 
 588 
2. Mean (± SEM) bone volumes (A) and percentage bone volumes (B) in a fixed length of 589 
midshaft metatarsal from fetuses infused for five days with either saline, leptin (LEP1 and 590 
LEP2) or leptin antagonist (SOLA).  For comparisons between saline and leptin treatment 591 
groups, compartments with different letters at the SEM bars are significantly different from 592 
each other (one-way ANOVA, p<0.05).  Compartments with no letters at the SEM bars are 593 
not significantly different from each other (p>0.05). 594 
 595 
3.  Mean (± SEM) porosity (A) and connectivity density (B) in the femur, and trabecular 596 
thickness (C) in the lumbar vertebra, of fetuses infused for five days with either saline or 597 
leptin (LEP1 and LEP2).  Columns with different letters are significantly different from each 598 
other (one-way ANOVA, p<0.05). 599 
 600 
4.  Mean (± SEM) trabecular number (A), trabecular spacing (B), degree of anisotrophy (C) 601 
and connectivity density (D) in the lumbar vertebra of fetuses infused for five days with either 602 
saline or leptin antagonist (SOLA).  *, significantly different from saline-treated fetuses 603 
(Student’s unpaired t-test, p<0.05). 604 
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 605 
5.  Mean (± SEM) porosity in the lumbar vertebra of fetuses infused for five days with either 606 
saline or leptin antagonist (SOLA).  *, significantly different from saline-treated fetuses of the 607 
same sex (two-way ANOVA, p<0.05); †, significantly different from male fetuses in the same 608 
treatment group (two-way ANOVA, p<0.05). 609 
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Table 1.  Mean (±SEM) plasma hormone and metabolite concentrations in the fetuses before (basal) and five days after infusion with saline, 610 
leptin (LEP1, LEP2) or leptin receptor antagonist (SOLA).  Basal = mean of days 0, -1 and -2.  In comparisons between saline and leptin 611 
treatment groups, values with different superscript letters are significantly different from each other (one-way ANOVA, p<0.05); † significant 612 
difference between fetuses treated with saline or leptin receptor antagonist (Student’s unpaired t-test, p<0.05); * significant difference from basal 613 
values (paired t-test, p<0.05). 614 
 615 
  Saline 
(n=9-11) 
LEP1 
(n=9-10) 
LEP2 
(n=7) 
SOLA 
(n=6) 
Leptin (ng/ml) 
Basal 0.69 ± 0.05 0.85 ± 0.03 0.90 ± 0.07 0.59 ± 0.03 
Day 5 0.72 ± 0.07a 4.66 ± 1.11*b 8.19 ± 1.73*c 7.93 ± 1.10*† 
Change +0.03 ± 0.04 a +3.81 ± 1.05b +7.29 ± 1.76c +7.35 ± 1.09† 
IGF-I (ng/ml) 
Basal 17.4 ± 1.7 14.0 ± 2.3 11.3 ± 1.3 16.1 ± 1.2 
Day 5 19.5 ± 2.4 14.8 ± 1.7 14.6 ± 2.8 14.9 ± 2.5 
Change +2.1 ± 1.7 +0.9 ± 1.2 +3.3 ± 3.6 -1.2 ± 2.0 
Osteocalcin (ng/ml) 
Basal 10.15 ± 0.44 11.95 ± 0.65 11.20 ± 0.55 10.95 ± 0.45 
Day 5 10.11 ± 0.39 11.86 ± 0.43 10.05 ± 1.13 10.16 ± 0.47 
Change -0.04 ± 0.41 -0.09 ± 0.41 -1.15 ± 0.87 -0.80 ± 0.40 
Calcium (mM) 
Basal 2.91 ± 0.03 2.86 ± 0.05 2.81 ± 0.07 2.89 ± 0.04 
Day 5 2.94 ± 0.05 2.93 ± 0.07 3.02 ± 0.17 2.85 ± 0.14 
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Change +0.03 ± 0.05 +0.08 ± 0.08 +0.23 ± 0.20 -0.04 ± 0.17 
Inorganic phosphate (mM) 
Basal 2.23 ± 0.09 2.40 ± 0.09 1.95 ± 0.10 2.19 ± 0.13 
Day 5 2.12 ± 0.10 2.21 ± 0.08 2.13 ± 0.11 1.99 ± 0.14 
Change -0.12 ± 0.07 -0.19 ± 0.09 +0.18 ± 0.15 -0.20 ± 0.12 
Alkaline phosphatase (U/l) 
Basal 172 ± 20 156 ± 15 122 ± 11 215 ± 16 
Day 5 201 ± 24* 190 ± 22* 166 ± 22* 244 ± 10* 
Change +28 ± 12 +34 ± 14 +44 ± 17 +30 ± 11 
616 
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Table 2.  Mean (±SEM) measurements of bodyweight and morphometry in the fetuses on the fifth day after infusion with saline, leptin (LEP1, 617 
LEP2) or leptin receptor antagonist (SOLA). 618 
 619 
 Saline 
(n=13) 
LEP1 
(n=10) 
LEP2 
(n=7) 
SOLA 
(n=6) 
Sex of fetuses (female:male) 7F:6M 5F:5M 4F:3M 3F:3M 
Bodyweight (kg) 2.76 ± 0.16 2.74 ± 0.12 2.32 ± 0.19 2.67 ± 0.14 
Crown-rump length (cm) 43.0 ± 1.0 43.5 ± 0.7 41.4 ± 1.1 44.6 ± 1.1 
Fore-limb lengths (cm)     
Humerus 9.2 ± 0.4 8.8 ± 0.1 8.4 ± 0.2 9.2 ± 0.8 
Radius 10.3 ± 0.3 10.5 ± 0.2 9.8 ± 0.3 10.5 ± 0.4 
Metacarpal 12.5 ± 0.5 12.5 ± 0.2 12.0 ± 0.4 11.8 ± 0.7 
Hind-limb lengths (cm)     
Femur 10.0 ± 0.5 10.2 ± 0.4 9.4 ± 0.3 10.8 ± 1.0 
Tibia 13.2 ± 0.4 13.5 ± 0.3 12.6 ± 0.4 12.9 ± 0.3 
Metatarsal 15.1 ± 0.5 15.0 ± 0.2 14.5 ± 0.4 14.0 ± 1.1 
620 
30 
 
Table 3.  Structural properties of femur, metatarsal and lumbar vertebra bones in fetuses infused for five days with saline or leptin (LEP1, 621 
LEP2).  In comparisons between saline and leptin groups, values with different superscript letters are significantly different from each other 622 
(two-way ANOVA, p<0.05).  † significantly different from male fetuses in same treatment group (two-way ANOVA, p<0.05). 623 
 624 
Bone property Bone type 
Saline 
(n=13) 
LEP1 
(n=10) 
LEP2 
(n=7) 
Effect of leptin infusion (p-value) 
Male 
(n=6) 
Female 
(n=7) 
Male 
(n=5) 
Female 
(n=5) 
Male 
(n=3) 
Female 
(n=4) 
Treatment Sex Interaction 
        
Midshaft total diameter 
(mm) 
Femur 
7.50 ± 0.26a 7.24 ± 0.14ab 6.58 ± 0.22b 
0.010 NS 0.014 
8.13 ± 0.23a 6.95 ± 0.33† 7.16 ± 0.25b 7.32 ± 0.17 6.31 ± 0.31b 6.79 ± 0.30 
Metatarsal 
7.11 ± 0.20 7.11 ± 0.16 6.64 ± 0.23 
NS (0.076) NS 
7.59 ± 0.12 6.64 ± 0.27 7.26 ± 0.27 6.95 ± 0.19 6.59 ± 0.36 6.68 ± 0.34 
Midshaft lumen diameter 
(mm) 
Femur 
3.61 ± 0.18 3.37 ± 0.21 3.40 ± 0.24 
NS NS (0.059) 
3.83 ± 0.26 3.43 ± 0.24 2.93 ± 0.15 3.81 ± 0.27 3.24 ± 0.37 3.52 ± 0.36 
Metatarsal 
4.34 ± 0.17 4.25 ± 0.10 4.14 ± 0.17 
NS NS 0.009 
4.78 ± 0.11a 3.89 ± 0.18† 4.20 ± 0.18b 4.30 ± 0.10 4.09 ± 0.22b 4.17 ± 0.27 
Midshaft wall thickness 
(mm) 
Femur 1.94 ± 0.12 1.93 ± 0.12 1.59 ± 0.09 (0.075) NS NS 
Metatarsal 1.39 ± 0.06 1.43 ± 0.06 1.25 ± 0.09 NS NS NS 
Body length (mm) 
Vertebrae 
7.83 ± 0.18 7.91 ± 0.13 7.31 ± 0.15 (0.091) NS NS 
Total bone volume (mm3) 394.7 ± 29.9 398.0 ± 28.6 311.6 ± 36.6 NS NS NS   
Bone volume/total 
volume (%) 
Femur 28.8 ± 2.5 30.0 ± 3.0 31.7 ± 3.9 NS NS NS 
Metatarsal 28.7 ± 1.8 30.0 ± 1.3 29.5 ± 1.8 NS NS NS 
Vertebra 31.6 ± 2.8 38.4 ± 3.5 41.8 ± 6.5 NS NS NS 
Bone surface/bone Femur 32.6 ± 1.4 37.0 ± 1.4 35.1 ± 1.4 (0.088) NS NS 
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volume (mm2/mm3) Metatarsal 30.0 ± 0.8 27.8 ± 1.1 29.7 ± 1.0 NS NS NS 
Vertebra 
27.0 ± 1.1 23.1 ± 1.4 23.4 ± 2.7 
(0.081) NS (0.057) 
29.4 ± 1.0 25.1 ± 1.6 20.9 ± 1.7 25.2 ± 1.9 20.6 ± 4.1 25.6 ± 3.7 
        
Trabecular thickness 
(mm)  
Femur 0.116 ± 0.003 0.110 ± 0.003 0.112 ± 0.004 NS NS NS 
Metatarsal 0.127 ± 0.003 0.137 ± 0.003 0.128 ± 0.003 (0.073) NS NS 
Trabecular number (/mm) 
Femur 2.44 ± 0.16 2.69 ± 0.21 2.78 ± 0.27 NS NS NS 
Metatarsal 2.26 ± 0.13 2.18 ± 0.07 2.30 ± 0.12 NS NS NS 
Vertebra 2.20 ± 0.13 2.24 ± 0.10 2.44 ± 0.20 NS NS NS 
Trabecular spacing (mm)  
Femur 0.26 ± 0.02 0.22 ± 0.02 0.22 ± 0.02 NS NS NS 
Metatarsal 0.27 ± 0.02 0.27 ± 0.01 0.27 ± 0.02 NS NS NS 
Vertebra 0.30 ± 0.02 0.30 ± 0.02 0.27 ± 0.04 NS NS NS 
Trabecular pattern factor 
(/mm)  
Femur 3.97 ± 1.09 2.23 ± 1.75 0.99 ± 2.50 NS NS NS 
Metatarsal 5.08 ± 0.82 4.97 ± 0.40 4.81 ± 0.58 NS NS NS 
Vertebra 2.96 ± 0.83 -1.04 ± 1.54 -0.84 ± 2.22 (0.069) NS NS 
        
Porosity (%) 
Metatarsal 0.007 ± 0.002 0.005 ± 0.001 0.004 ± 0.002 NS NS NS 
Vertebra 0.007 ± 0.001 0.029 ± 0.012 0.045 ± 0.033 NS NS NS 
Structural model index 
Femur 1.32 ± 0.13 1.37 ± 0.15 1.22 ± 0.17 NS NS NS 
Metatarsal 1.61 ± 0.08 1.68 ± 0.06 1.55 ± 0.08 NS NS NS 
Vertebra 1.29 ± 0.12 0.89 ± 0.15 0.69 ± 0.35 (0.077) NS NS 
Degree of anisotropy 
Femur 2.15 ± 0.05 1.99 ± 0.06 2.01 ± 0.12 NS NS NS 
Metatarsal 1.43 ± 0.07 1.65 ± 0.07 1.64 ± 0.09 (0.080) NS NS 
Vertebra 1.53 ± 0.06 1.44 ± 0.06 1.50 ± 0.14 NS NS NS 
 
Connectivity density 
(/mm3) 
Metatarsal 78.1 ± 14.1 65.6 ± 7.3 69.7 ± 7.7 NS NS NS 
Vertebra 52.9 ± 6.8 72.7 ± 19.1 66.0 ± 15.9 NS NS NS 
625 
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Table 4.  Structural properties of femur, metatarsal and lumbar vertebra bones in fetuses infused for five days with saline or a leptin receptor 626 
antagonist (SOLA).  † significantly different from male fetuses in same treatment group (two-way ANOVA, p<0.05). 627 
Bone property Bone type 
Saline 
(n=13) 
SOLA 
(n=6) 
Effect of SOLA infusion (p-value) 
Male 
(n=6) 
Female 
(n=7) 
Male 
(n=3) 
Female 
(n=3) 
Treatment Sex Interaction 
       
Midshaft total diameter (mm) 
Femur 
7.50 ± 0.26 7.62 ± 0.23 
NS 0.006 NS 
8.13 ± 0.23 6.95 ± 0.33† 8.06 ± 0.10 7.17 ± 0.24† 
Metatarsal 
7.11 ± 0.20 6.98 ± 0.30 
NS 0.001 NS 
7.59 ± 0.12 6.64 ± 0.27† 7.61 ± 0.25 6.35 ± 0.07† 
Midshaft lumen diameter (mm) 
Femur 3.61 ± 0.18 3.26 ± 0.16 NS NS NS 
Metatarsal 
4.34 ± 0.17 4.25 ± 0.20 
NS 0.001 NS 
4.78 ± 0.11 3.89 ± 0.18† 4.66 ± 0.19 3.84 ± 0.03† 
Midshaft wall thickness (mm) 
Femur 1.94 ± 0.12 2.18 ± 0.10 NS NS NS 
Metatarsal 1.39 ± 0.06 1.37 ± 0.08 NS NS NS 
Body length (mm) Vertebra 7.83 ± 0.18 8.06 ± 0.40 (0.091) NS NS 
Total bone volume (mm3) 394.7 ± 29.9 454.7 ± 54.7 NS NS NS 
Bone volume/total volume (%) 
Femur 28.8 ± 2.5 33.1 ± 1.7 NS NS NS 
Metatarsal 28.7 ± 1.8 23.8 ± 1.5 NS NS NS 
Vertebra 
31.6 ± 2.8 38.1 ± 3.3 
NS (0.097) NS 
26.6 ± 2.6 35.9 ± 4.2 34.9 ± 3.2 41.4 ± 5.8 
Bone surface/bone volume 
(mm2/mm3) 
Femur 32.6 ± 1.4 29.6 ± 1.3 NS NS NS 
Metatarsal 30.0 ± 0.8 32.1 ± 1.5 NS NS NS 
Vertebra 
27.0 ± 1.1 28.0 ± 1.3 
NS 0.041 NS 
29.4 ± 1.0 25.1 ± 1.6† 29.6 ± 1.4 26.3 ± 1.9 
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Trabecular thickness (mm)  
Femur 0.116 ± 0.003 0.121 ± 0.004 NS NS NS 
Metatarsal 0.127 ± 0.003 0.120 ± 0.003 NS NS NS 
Vertebra 0.142 ± 0.005 0.142 ± 0.008 NS NS NS 
Trabecular number (/mm) 
Femur 2.44 ± 0.16 2.73 ± 0.06 NS NS NS 
Metatarsal 2.26 ± 0.13 1.99 ± 0.09 NS NS NS 
Trabecular spacing (mm)  
Femur 0.26 ± 0.02 0.23 ± 0.01 NS NS NS 
Metatarsal 0.27 ± 0.02 0.29 ± 0.02 NS NS NS 
Trabecular pattern factor 
(/mm) 
Femur 3.97 ± 1.09 2.41 ± 0.60 NS NS NS 
Metatarsal 5.08 ± 0.82 7.77 ± 1.21 (0.099) NS NS 
Vertebra 
2.96 ± 0.83 1.68 ± 0.82 
NS (0.058) NS 
4.50 ± 0.90 1.64 ± 1.16 2.79 ± 1.17 0.57 ± 0.88 
       
Porosity (%)  
Femur 0.005 ± 0.002 0.003 ± 0.001 NS NS NS 
Metatarsal 0.007 ± 0.002 0.002 ± 0.001 NS NS NS 
Structural model index 
Femur 1.32 ± 0.13 1.13 ± 0.07 NS NS NS 
Metatarsal 1.61 ± 0.08 1.77 ± 0.14 NS NS NS 
Vertebra 
1.29 ± 0.12 1.38 ± 0.16 
NS 0.037 NS 
1.52 ± 0.12 1.09 ± 0.17 1.60 ± 0.27 1.16 ± 0.10 
Degree of anisotropy 
Femur 2.15 ± 0.05 2.24 ± 0.06 NS NS NS 
Metatarsal 1.43 ± 0.07 1.36 ± 0.05 NS NS NS 
Connectivity density (/mm3) 
Femur 68.5 ± 7.9 63.5 ± 2.65 NS NS NS 
Metatarsal 78.1 ± 14.1 53.2 ± 7.8 NS NS NS 
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Figure 1. Mean (± SEM) bone volumes (A) and percentage bone volumes (B) in a fixed length of 
midshaft femur from fetuses infused for five days with either saline, leptin (LEP1 and LEP2) or leptin 
antagonist (SOLA).  For comparisons between saline and leptin treatment groups, columns with 
different letters are significantly different from each other; uppercase letters indicate differences in 
the total volume, and lowercase letters at the SEM bars indicate differences in volume 
compartments (one-way ANOVA, p<0.05).  Compartments with no letters at the SEM bars are not 
significantly different from each other (p>0.05).
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Figure 2. Mean (± SEM) bone volumes (A) and percentage bone volumes (B) in a fixed length of 
midshaft metatarsal from fetuses infused for five days with either saline, leptin (LEP1 and LEP2) or 
leptin antagonist (SOLA).  For comparisons between saline and leptin treatment groups, 
compartments with different letters at the SEM bars are significantly different from each other (one-
way ANOVA, p<0.05).  Compartments with no letters at the SEM bars are not significantly different 
from each other (p>0.05).
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Figure 3. Mean (± SEM) porosity (A) and connectivity density (B) in the femur, and trabecular 
thickness (C) in the lumbar vertebra, of fetuses infused for five five days with either saline or leptin 
(LEP1 and LEP2).  Columns with different letters are significantly different from each other (one-
way ANOVA, p<0.05). 
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Figure 4. Mean (± SEM) porosity in the lumbar vertebra of fetuses infused for five days with either 
saline or leptin antagonist (SOLA).  *, significantly different from saline-treated fetuses of the same 
sex (two-way ANOVA, p<0.05); †, significantly different from male fetuses in the same treatment 
group (two-way ANOVA, p<0.05).
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Figure 5. Mean (± SEM) porosity in the lumbar vertebra of fetuses infused for five days with either 
saline or leptin antagonist (SOLA).  *, significantly different from saline-treated fetuses (p<0.05); †, 
significantly different from male fetuses in the same treatment group (p<0.05). 
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